Kurma plans to raise a total of 250 million euros ($276 million) for the fund, dubbed Biofund IV, which would make it the ...

GigaGen’s prior work with the DOD produced polyclonal antibodies that can neutralize two botulinum neurotoxins, which are ...

Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. | ...

The FDA is getting the word out on a mandatory software update from Philips for its Trilogy line of portable life support ...

Big Pharma is investing heavily in AI to slash development timelines and foster innovation. | Big Pharma is investing heavily ...

Frazier Life Sciences has sourced a further $630 million for its fund focused on small and mid-cap biotechs. | Frazier Life ...

Lundbeck has tapped Charles River Laboratories’ artificial intelligence capabilities to aid the discovery of neuroscience ...

The COVID-19 pandemic made the public acutely aware of how vulnerable their noses are. | The COVID-19 pandemic made us ...

Triveni Bio has roped in $115 million in series B funds to advance preclinical antibody programs designed to treat ...

Synchron has reported that its miniature brain-computer interface implant, threaded up through the blood vessels to help read the activity of the motor cortex, showed no major side effects in a ...

Zephyrm Bioscience is gusting toward the Hong Kong stock exchange, filing (PDF) for an IPO to bankroll phase 3 trials of its ...

Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer ...